Literature DB >> 11876300

Preparation of recombinant RNase single-chain antibody fusion proteins.

Dianne L Newton1, Susanna M Rybak.   

Abstract

This article describes the construction, expression, and purification of RNase single-chain antibody fusion proteins. To construct a fusion protein, the gene for each moiety, the RNase and the binding ligand, is modified separately to contain complementary DNA encoding a 13 amino acid spacer that separates the RNase from the binding moiety. Appropriate restriction enzyme sites for cloning into the vector are also added. The modified DNA is combined and fused using the PCR technique of splicing by overlap extension (1). The resulting DNA construct is expressed in inclusion bodies in BL21(DE3) bacteria that are specifically engineered for the expression of toxic proteins (2). After isolation and purification of the inclusion bodies, the fusion protein is solubilized, denatured, and renatured. The renatured RNase fusion protein mixture is purified to homogeneity by two chromatography steps. The first column, a CM-Sephadex C-50 or a heparin Sepharose column, eliminates the majority of contaminating proteins while the second column, an affinity column (Ni2+-NTA agarose), results in the final purification of the RNase fusion protein.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11876300     DOI: 10.1385/MB:20:1:063

Source DB:  PubMed          Journal:  Mol Biotechnol        ISSN: 1073-6085            Impact factor:   2.695


  38 in total

1.  Human pancreatic RNase1-human epidermal growth factor fusion: an entirely human 'immunotoxin analog' with cytotoxic properties against squamous cell carcinomas.

Authors:  K Psarras; M Ueda; T Yamamura; S Ozawa; M Kitajima; S Aiso; S Komatsu; M Seno
Journal:  Protein Eng       Date:  1998-12

2.  Antitransferrin receptor antibody-RNase fusion protein expressed in the mammary gland of transgenic mice.

Authors:  D L Newton; D Pollock; P DiTullio; Y Echelard; M Harvey; B Wilburn; J Williams; H R Hoogenboom; J C Raus; H M Meade; S M Rybak
Journal:  J Immunol Methods       Date:  1999-12-10       Impact factor: 2.303

3.  Interaction of rifamycin with bacterial RNA polymerase.

Authors:  W Wehrli; F Knüsel; K Schmid; M Staehelin
Journal:  Proc Natl Acad Sci U S A       Date:  1968-10       Impact factor: 11.205

Review 4.  Targeted therapy of cancer with recombinant immunotoxins.

Authors:  I Pastan
Journal:  Biochim Biophys Acta       Date:  1997-10-24

5.  Amino acid sequence of human tumor derived angiogenin.

Authors:  D J Strydom; J W Fett; R R Lobb; E M Alderman; J L Bethune; J F Riordan; B L Vallee
Journal:  Biochemistry       Date:  1985-09-24       Impact factor: 3.162

6.  Sequence of the cDNA and gene for angiogenin, a human angiogenesis factor.

Authors:  K Kurachi; E W Davie; D J Strydom; J F Riordan; B L Vallee
Journal:  Biochemistry       Date:  1985-09-24       Impact factor: 3.162

7.  Comprehensive pharmacokinetics of a humanized antibody and analysis of residual anti-idiotypic responses.

Authors:  S Stephens; S Emtage; O Vetterlein; L Chaplin; C Bebbington; A Nesbitt; M Sopwith; D Athwal; C Novak; M Bodmer
Journal:  Immunology       Date:  1995-08       Impact factor: 7.397

8.  Comparison of RNases and toxins upon injection into Xenopus oocytes.

Authors:  S K Saxena; S M Rybak; G Winkler; H M Meade; P McGray; R J Youle; E J Ackerman
Journal:  J Biol Chem       Date:  1991-11-05       Impact factor: 5.157

9.  Angiogenin single-chain immunofusions: influence of peptide linkers and spacers between fusion protein domains.

Authors:  D L Newton; Y Xue; K A Olson; J W Fett; S M Rybak
Journal:  Biochemistry       Date:  1996-01-16       Impact factor: 3.162

10.  Toxicity and immunogenicity of monoclonal antimelanoma antibody-ricin A chain immunotoxin in rats.

Authors:  S Harkonen; J Stoudemire; R Mischak; L E Spitler; H Lopez; P Scannon
Journal:  Cancer Res       Date:  1987-03-01       Impact factor: 12.701

View more
  2 in total

Review 1.  Killing of cancer cells through the use of eukaryotic expression vectors harbouring genes encoding nucleases and ribonuclease inhibitor.

Authors:  Elena M Glinka
Journal:  Tumour Biol       Date:  2015-04-01

2.  Probing the antigenicity of E. coli L-asparaginase by mutational analysis.

Authors:  Chen Jianhua; Wei Yujun; Jia Ruibo; Wang Min; Wu Wutong
Journal:  Mol Biotechnol       Date:  2006-05       Impact factor: 2.695

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.